XORTX outlines Canadian trial plan for XORTX Therapeutics stock

Published on 10/15/2026 at 13:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

XORTX outlined a Canadian trial plan on October 8. XORTX Therapeutics stock costs EUR 1.39 on October 15, 2026, with Q2 net loss at USD 1.69 million.

Regulatory milestones and finances

XORTX outlined a two-part Canadian gout study on October 8, 2026.
XORTX posted a USD 1.69 million net loss for the second quarter of 2026.
XORTX Therapeutics stock traded at EUR 1.39 at 1:43 p.m. CEST at Lang & Schwarz on October 15, 2026.

XRTX, CA98420Q4051, Illustration mit AI erstellt.

XORTX Therapeutics (CA98420Q4051) was trading at EUR 1.39 at Lang & Schwarz on October 15, 2026, at 1:43 p.m. CEST. The company outlined a Canadian trial application for its XRx-026 gout program on October 8, 2026, according to StockTitan. The regulatory step gives the small biotechnology company a concrete development milestone, but the program remains clinical.

Canadian trial plan has two parts

The October 8 filing described a planned two-part XRX-OXY-102 study evaluating XORLO, XORTX's formulation of oxypurinol for gout. The first part is planned in Canada and is intended to support later clinical data for a planned New Drug Application to the U.S. Food and Drug Administration, StockTitan reported.

What does the filing change?

The filing moves the Canadian regulatory path alongside the U.S. plan rather than replacing it. XORTX said potential commercialization partners had shown interest, while the October 8 filing described the discussions as a development-stage opportunity rather than a completed transaction.

Three milestones shape the pipeline

The company began clinical and commercial manufacturing of XORLO on September 10, 2026. On September 18, 2026, it outlined a planned FDA investigational new drug submission for the gout program and cited a U.S. gout market opportunity exceeding USD 700 million. The October 8 Canadian trial application was the latest of the three dated milestones.

Results and the next reporting date

For the second quarter ended June 30, 2026, XORTX reported a net loss attributable to common shareholders of USD 1.69 million and diluted loss per share of USD 1.05. The company also held USD 994,045 in cash at June 30, 2026. TradingView lists November 12, 2026, as the next expected earnings date.

Price and capital position

XORTX is listed on Nasdaq under XRTX, according to the company investor page. The primary-market quote was USD 1.56 on October 14, 2026, at 4:00 p.m. EDT, with a USD 1.36 to USD 7.05 52-week range and market capitalization of USD 2.8 million. The euro quotation was EUR 1.39 at Lang & Schwarz on October 15, 2026, at 1:43 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of XORTX Therapeutics stock.